Dovato (Dolutegravir/Lamivudine) for HIV

Overview
Dovato is a prescription drug approved by the Food and Drug Administration (FDA) to treat HIV-1 infection in adults. Dovato is a combination drug composed of Dolutegravir and Lamivudine, which are also known respectively by the abbreviations DTG and 3TC. Lamivudine is an antiviral medication of the nucleoside reverse transcriptase inhibitor (NRTI) class. Dolutegravir is an antiviral medication of the integrase strand transfer inhibitor (INSTI) class. Both drugs are believed to work by preventing HIV from replicating in cells.

How do I take it?
Prescribing information states that Dovato is taken once daily. Dovato comes in tablet form.

Side effects
The FDA-approved label for Dovato lists common side effects including headache, fatigue, diarrhea, nausea, and insomnia. Rare but serious side effects listed for Dovato include severe hypersensitivity reactions, lactic acidosis (a metabolic disorder), liver problems, and severe exacerbation of hepatitis B.

For more details about this treatment, visit:

Dovato – ViiV Healthcare